Related Experiment Video
Updated: Sep 26, 2025
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Validation of an LC-MS/MS Method for the Quantification of the CK2 Inhibitor Silmitasertib (CX-4945) in Human Plasma
Rico Schwarz1, Anna Richter2, Elisabeth R D Ito1
1Institute of Pharmacology and Toxicology, Rostock University Medical Center, 18057 Rostock, Germany.
Abstract:
Silmitasertib (CX-4945) is currently being investigated in clinical trials against various types of cancer. The U.S. Food and Drug Administration (FDA) has already granted orphan drug designation to the compound for the treatment of advanced cholangiocarcinoma, medulloblastoma, and biliary tract cancer. Silmitasertib inhibits the serine/threonine protein kinase CK2, which exerts a proliferation-promoting and anti-apoptotic effect on cancer cells. In view of current and future applications, the measurement of silmitasertib levels in plasma is expected to play an important role in the evaluation of therapeutic and toxic concentrations in cancer patients. In the present work, we therefore present an LC-MS/MS method for the quantification of silmitasertib in human plasma. Using a simple liquid-liquid extraction with ethyl acetate and a mixture of n-hexane and ethyl acetate, this method can be performed in any laboratory with mass spectrometry. The validation was carried out according to the FDA guideline.
Insights
A new LC-MS/MS method quantifies silmitasertib (CX-4945) in human plasma. This assay is crucial for monitoring therapeutic drug levels in cancer patients undergoing treatment.
Area of Science:
- Pharmacology
- Analytical Chemistry
- Oncology
Background:
- Silmitasertib (CX-4945) is an investigational cancer therapeutic targeting protein kinase CK2.
- CK2 inhibition affects cancer cell proliferation and apoptosis, making it a target for various cancers.
- The U.S. FDA has granted orphan drug designation for silmitasertib in cholangiocarcinoma, medulloblastoma, and biliary tract cancer.
Purpose of the Study:
- To develop and validate a reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.
- To quantify silmitasertib concentrations in human plasma samples.
- To support clinical trial evaluations of silmitasertib's therapeutic and toxic ranges.
Main Methods:
- Liquid-liquid extraction using ethyl acetate and a hexane/ethyl acetate mixture.
- Quantification via liquid chromatography-tandem mass spectrometry (LC-MS/MS).
- Method validation conducted following FDA guidelines.
Main Results:
- A validated LC-MS/MS method for silmitasertib quantification in human plasma was established.
- The method utilizes a straightforward sample preparation technique.
- The assay is suitable for routine laboratory use in clinical settings.
Conclusions:
- The developed LC-MS/MS method provides a robust tool for measuring silmitasertib plasma levels.
- Accurate quantification is essential for optimizing cancer patient treatment with silmitasertib.
- This assay facilitates therapeutic drug monitoring and safety assessments in clinical applications.
More Related Videos
10:38Simultaneous Quantification of Selected Kynurenines Analyzed by Liquid Chromatography-Mass Spectrometry in Medium Collected from Cancer Cell Cultures
Published on: May 9, 2020
08:06Absolute Quantification of Cell-Free Protein Synthesis Metabolism by Reversed-Phase Liquid Chromatography-Mass Spectrometry
Published on: October 25, 2019